Suvretta Capital Management LLC has recently announced that it has increased stake in Kura Oncology Inc (NASDAQ:KURA) by 4.37%. After grabbing 7.34 million shares, the institutional investor is now in possession of 0.31 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 9.88% having worth around $105.49 million. Moreover, BlackRock Fund Advisors increased its share by 0.6 million to have a control over 5.57 million shares. And The Vanguard Group, Inc. raised its holdings to 0.27 million shares by acquiring 3.86 million shares or 5.19% of the stake.
Kura Oncology Inc (KURA) concluded trading on Wednesday at a closing price of $19.61, with 16.0 million shares of worth about $313.68 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 95.90% during that period and On Wednesday, January 24 the price saw a gain of about 46.13%. Currently the company’s common shares owned by public are about 68.31M shares, out of which, 65.73M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 18 times over the past 12 months. They bought 415,269 shares in 6 of the transactions. In 12 selling transactions, insiders dumped 904,678 shares.
Vanguard Total Stock Market ETF, iShares Russell 2000 ETF, and SPDR S&P Biotech ETF are the top 3 mutual funds which are holding stakes in Kura Oncology Inc Vanguard Total Stock Market ETF is currently holding 2.21 million shares of worth totaling $31.74 million. The company recently came buying 0.0 shares which brought its stake up to 2.97% of the company’s outstanding shares. iShares Russell 2000 ETF sold 5058.0 shares, after which its hold over company’s outstanding shares shrunk to 2.57%, leaving 1.91 million shares with the mutual fund that have a worth of about $27.48 million. SPDR S&P Biotech ETF, after selling 1.34 million shares, have now control over 1.81% of the stake in the company. It holds 12960.0 shares of worth $19.3 million.
However, the stock later moved at a day high price of 21.40, or with a gain of 46.13%. Stock saw a price change of 32.86% in past 5 days and over the past one month there was a price change of 56.01%. Year-to-date (YTD), KURA shares are showing a performance of 36.37% which increased to 40.37% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $7.41 but also hit the highest price of $15.96 during that period. The average intraday trading volume for Kura Oncology Inc shares is 1.01 million. The stock is currently trading 33.23% above its 20-day simple moving average (SMA20), while that difference is up 61.92% for SMA50 and it goes to 79.97% higher than SMA200.
Suvretta Capital Management LLC acquired 7.34 million shares of Kura Oncology Inc having value of about $105.49 million. Data submitted at the U.S SEC by Suvretta Capital Management LLC revealed that the firm now holds 0.31 million shares in the company valued at close to $6028172.83, or have control over 4.37% stake in the company. Kura Oncology Inc (NASDAQ: KURA) currently have 68.31M outstanding shares and institutions hold larger chunk of about 91.14% of that. Holding of mutual funds in the company is about 24.20% while other institutional holders and individual stake holders have control over 67.42% and 10.23% of the stake respectively.
The stock has a current market capitalization of $1.46B and its 3Y-monthly beta is at 0.83. It has posted earnings per share of -$2.02 in the same period. It has Quick Ratio of 16.71 while making debt-to-equity ratio of 0.04. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for KURA, volatility over the week remained 9.22% while standing at 5.53% over the month.
Analysts are in expectations that Kura Oncology Inc (KURA) stock would likely to be making an EPS of -$0.55 in the current quarter, while forecast for next quarter EPS is -$0.58 and it is -$2.26 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.68 which is -$0.49 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.49 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -2.11% while it is estimated to decrease by -8.00% in next year. EPS is likely to grow at an annualized rate of 19.93% for next 5-years, compared to annual growth of -5.93% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Mizuho on December 22, 2023 offering a Buy rating for the stock and assigned a target price of $26 to it.
